Chemomab Therapeutics Ltd.

Chemomab Therapeutics Ltd. is a clinical-stage biotechnology company specializing in the discovery and development of innovative therapeutics targeting fibrosis-related and fibro-inflammatory diseases, which represent areas with significant unmet medical needs. The company's lead candidate, CM-101 (also known as nebokitug), is a first-in-class monoclonal antibody that neutralizes the soluble protein CCL24, a key driver of fibrosis and inflammation. This novel therapeutic approach aims to modify the progression of diseases such as liver fibrosis, systemic sclerosis, and primary sclerosing cholangitis, the latter being a rare and severe liver condition. Chemomab's clinical pipeline includes multiple ongoing Phase 2 trials for CM-101 across different fibrotic conditions, with positive results reported, positioning the therapy for potential Phase 3 trials. The company is advancing its programs with orphan drug and fast-track designations from regulatory agencies, underscoring its potential to address serious fibro-inflammatory diseases that currently have limited treatment options. Chemomab continues to seek strategic collaborations to further develop and commercialize its innovative therapies.

Sector

Healthcare

Industry

Biotechnology

CEO

Dr. Adi Mor George Ph.D.

Headquarters

Tel Aviv, Israel

Website

www.chemomab.com